Positron emission tomographic scans in lymphoma: Convention and controversy

Stephen M. Ansell, James O. Armitage

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.

Original languageEnglish (US)
Pages (from-to)571-580
Number of pages10
JournalMayo Clinic Proceedings
Volume87
Issue number6
DOIs
StatePublished - Jun 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Positron emission tomographic scans in lymphoma: Convention and controversy'. Together they form a unique fingerprint.

  • Cite this